> ## Content Index > Fetch the complete content index at: https://dotsexual.com/llms.txt > Use this file to discover other available public pages before exploring further. # Testosterone Prescription Checklist: The Two-Morning-Test Rule (Movember 2026) - URL: https://dotsexual.com/testosterone-prescription-checklist-movember-2026/ - Published: 2026-10-31T10:30:00.000Z - Updated: 2026-10-31T10:30:00.000Z - Description: Only 21.8% of men started on testosterone in a 300,277-patient 2026 audit had the two early-morning labs the AUA and Endocrine Society require. The 12-point checklist for any Movember clinic, the sperm and haematocrit timeline, and what the 2026 FDA label moves did not change. - Author: Dot Research Desk - Tags: Research, Normal or Not?, How Long? Quick Answer (Checked 31 October 2026) **Movember 2026 begins on Sunday, 1 November, and this year the "low T" clinic offer is the loudest men's-health pitch in the feed. A 27 October 2026 analysis of 300,277 men by Epic Research found that only 21.8% of men starting testosterone had the two low results the guidelines require first, while 82.6% had at least one blood test. The clinically important findings:** 1. **One Blood Draw Is Not a Diagnosis:** the [AUA guideline](https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline?ref=dotsexual.com) requires symptoms plus **two early-morning total testosterone measurements consistently below 300 ng/dL** (the [Endocrine Society](https://www.endocrine.org/guidelines-and-review-tests/endocrine-clinical-practice-guidelines?ref=dotsexual.com) uses 264 ng/dL as its harmonised cut-off). Testosterone follows a circadian rhythm that can swing results by tens of percent, so a 4 p.m. draw in a tired man is the single most common diagnostic error. The [Endocrine Society's 16 July 2026 statement](https://www.endocrine.org/news-and-advocacy/news-room/2026/statement-on-testosterone-replacement-therapy?ref=dotsexual.com) repeats this and adds: use a CDC-standardised (HoST-certified) assay, and do not screen asymptomatic men at population level. 2. **Testosterone Is Not Contraception, and It Is a Fertility Decision:** exogenous testosterone suppresses LH and FSH within 2 to 4 weeks and can drive sperm counts to zero, with **65% of men azoospermic by about 6 months** at contraceptive doses and a mean time to azoospermia of **\~120 days**. Yet **5 to 10% of men keep enough sperm production to cause an unplanned pregnancy**, so a condom or a partner's method is still needed if pregnancy is not wanted. Recovery after stopping is documented at **67% within 6 months, 90% within 12, 96% within 16 and 100% within 24 months** in the pooled contraceptive-trial data, so "I'll stop when we want a baby" is a gamble, not a plan. 3. **The Monitoring Numbers Are Public, so Ask for Them by Name:** baseline haemoglobin/haematocrit (therapy withheld above **50%** until explained, and **haematocrit ≥54% on treatment mandates intervention** such as dose reduction, longer injection interval or phlebotomy), PSA before starting in men over 40, testosterone re-checked **2 to 4 weeks** after starting a gel/patch, blood-pressure checks after the [February 2025 FDA class-wide blood-pressure labelling change](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-issues-class-wide-labeling-changes-testosterone-products?ref=dotsexual.com), and a fertility conversation before the first prescription. Two regulatory events in 2026 have poured fuel onto the testosterone market. On [16 April 2026 the FDA invited manufacturers](https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men?ref=dotsexual.com) to submit evidence for a new indication: low libido in men with *idiopathic* hypogonadism, meaning low testosterone with no structural or genetic cause identified, and on [18 June 2026 HHS said it wants the "safety and effectiveness have not been established for age-related low testosterone" limitation of use removed](https://www.reuters.com/business/healthcare-pharmaceuticals/us-health-department-proposes-testosterone-therapy-label-updates-2026-06-18/?ref=dotsexual.com), the prostate-cancer contraindication narrowed to metastatic disease, and the enlarged-prostate warning softened. None of that is an approval; all of it is being marketed as one. Then, on **27 October 2026**, [Epic Research published the real-world consequence](https://www.epicresearch.org/articles/most-men-starting-testosterone-had-prior-testing-but-only-1-in-5-met-the-two-test-standard/?ref=dotsexual.com) of that demand in **300,277 men** who received a new testosterone prescription between January 2017 and June 2026 across more than 310 million patient records. In the first half of 2026, 82.6% had at least one testosterone test in the preceding year, 40.8% had two or more on separate days, but **only 21.8% had the two low results (under 300 ng/dL) within six months before the prescription** that the [AUA guideline](https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline?ref=dotsexual.com) describes. That share rose from 16.9% in 2017 to a peak of 22.8% in 2024, then slipped back. Men in their 30s were the most likely to have a documented low result (66.2%) and men 75 and over the least (58.8%). The authors flag one limitation that matters a lot here: direct-to-consumer-only prescriptions, bought outside those health systems, are largely missing from the data, so the true figure for "tested before treated" is probably worse, not better. Here is the same evidence turned into a checklist you can take into the appointment, plus the fertility and contraception consequences no advert mentions. ## 1\. What the guidelines require before the first dose | Requirement | AUA (2018, validity affirmed 2024) | Endocrine Society (2018 guideline + 16 July 2026 statement) | US FDA labelling position in 2026 | What to ask for at the visit | | -------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------ | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------- | | **Total testosterone threshold** | Consistently **below 300 ng/dL (10.4 nmol/L)** as the reasonable cut-off. | **264 ng/dL (9.2 nmol/L)** as the harmonised lower limit of normal. | No numeric threshold in the label; products are indicated for deficiency with an associated medical condition. | "Which threshold are you using, and is my number below it twice?" | | **Number and timing of draws** | **At least two** measurements, **early morning**, ideally same lab and same assay; a third is allowed if the first is low and the second normal. | Two early-morning **fasting** samples; the July 2026 statement says the same standard applies at every age. | Labels require laboratory confirmation of hypogonadism before prescribing; the FDA does not endorse single-read testing. | Book both draws **between 7 and 10 a.m.** on separate days before the prescription. | | **Symptoms required?** | Yes: a low level **and** compatible signs/symptoms; levels alone do not diagnose. | Yes, and "age-related", "late-onset" and "functional" hypogonadism are called operationally ill-defined; reversible causes (obesity, opioids, corticosteroids) come first. | April 2026: manufacturers may now seek evidence for low libido in *idiopathic* hypogonadism. That is an invitation to submit data, not an approved use. | Name the specific symptom and how long it has been present; vague fatigue scores are not a diagnosis. | | **Baseline safety panel** | **Haemoglobin/haematocrit** (withhold if Hct >50% until explained); **PSA** in men over 40; LH/FSH to separate primary from secondary. | Haematocrit, lipids where indicated, prostate assessment per risk; prolactin and iron studies when secondary causes are possible. | Class-wide label requires **blood-pressure** warnings after the ABPM studies; haematocrit monitoring is in every product label. | Ask to see the actual values printed in your portal, not a summary email. | | **Fertility conversation** | Explicit: exogenous testosterone **should not be prescribed to men currently trying to conceive**. | Counselling on fertility risk before starting; alternatives (clomiphene, hCG) where conception is wanted. | No label indication for fertility; secondary testicular failure and suppressed sperm output are recognised class effects. | "Do I want children in the next two years?" must be answered **before** the first dose, ideally with a baseline semen analysis. | ## 2\. Where the real-world data diverges from the guideline - **Prescribing volume.** US testosterone prescriptions rose from about **7.3 million in 2019 to more than 11 million in 2024**, roughly a 50% increase in five years, with **\~325 new dedicated "low T" clinics** opened since early 2024 ([Miami Herald analysis, June 2026, citing PLoS One 2024 and STAT reporting](https://www.miamiherald.com/living/article316019857.html?ref=dotsexual.com)). A 2024 *PLoS One* study found a 27% rise in TRT patients from 2018 to 2022, with the sharpest growth in men aged 35 to 44 (up 58%). - **Young men are the fastest-growing group.** [Truveta research (September 2026)](https://www.truveta.com/blog/research/testosterone-rise-adults/?ref=dotsexual.com) found prescribing among adults aged 18 to 34 **more than doubled**, from 1.4 to 3.2 per 1,000 patients between January 2018 and July 2026 (+121.8%), and injectable testosterone dispensing rose 88% since 2018 versus 27% for topical gels. - **The UK shows the same curve.** NHS testosterone prescriptions rose **52% between 2020/21 and 2024/25**, while clinicians warn that commercial testing companies claiming "up to 30% of men over 40 have low testosterone" sit against clinical data suggesting **only about 2% of men aged 40 to 79** have a genuine deficiency ([Brit Brief, 14 October 2026](https://britbrief.co.uk/health/public/testosterone-supplement-surge-sparks-health-warning.html?ref=dotsexual.com)). - **Guideline-concordant workups are the exception, not the rule.** At ENDO 2026, researchers reporting on 200 men with a hypogonadism diagnosis and a first testosterone prescription found only **12%** had two low morning levels, LH and/or FSH measured, and no contraindications; assessment had been triggered by fatigue (63%), erectile complaints (62%), low libido (54%) or patient request (25%) ([Renal & Urology News, 16 June 2026](https://www.renalandurologynews.com/news/endo-few-men-receiving-testosterone-undergo-guideline-concordant-diagnostic-testing/?ref=dotsexual.com)). Epic's 21.8% figure now brackets that finding from the population side. ## 3\. The timeline testosterone changes: sperm, haematocrit, blood pressure, libido | Time on Therapy | Fertility / Semen Changes (the part ads omit) | Safety Monitoring Due | Sexual-Function Expectation | | --------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | | **Weeks 1-4** | LH and FSH fall; intratesticular testosterone drops even as blood testosterone rises. Semen analysis still usually normal, because suppression is invisible without a test. | Baseline Hct recorded; topical formulations re-checked at **2-4 weeks** for level, applying the gel on the draw day. | Erections depend on androgen status *and* vascular/psychological factors; men whose erections were normal when awake usually do not see a dramatic change from testosterone alone. | | **Months 2-3** | Sperm concentration measurably declining; **mean time to azoospermia \~120 days** in the WHO contraceptive-programme data, with 65% of men azoospermic by 6 months on 200 mg every 2 weeks of testosterone enanthate ([Crosnoe, *Transl Androl Urol*](https://tau.amegroups.org/article/view/2249/html?ref=dotsexual.com)). | First scheduled review: symptoms, level, **haematocrit**, blood pressure; acne, oedema, sleep apnoea review. | If libido does not move at all despite levels in the mid-normal range, the androgen question is probably not the driving one. See the "energy is the least-supported benefit" note below. | | **Months 4-6** | Most men are severely oligospermic or azoospermic; testicular volume typically decreases 10-20%. **5-10% still produce enough sperm to cause pregnancy, because testosterone is not contraception.** | **Hct ≥54% mandates intervention** (dose reduction, longer interval, sometimes therapeutic phlebotomy or haematology referral); AUA follow-up windows of every 6-12 months for haematocrit. | Ejaculate volume commonly falls, frequently misread as "better control", sometimes as a new problem. | | **Stopping (the recovery clock)** | Pooled contraceptive-trial recovery: **67% back to ≥20 million/mL within 6 months, 90% by 12, 96% by 16, 100% by 24 months**; median recovery \~196 days, with injections clearing faster than pellets and men who used gels taking longer in one series. Longer exposure, older age and pre-existing subfertility predict slower recovery ([Crosnoe 2013](https://tau.amegroups.org/article/view/2249/html?ref=dotsexual.com)). | Expect a hypogonadal dip (fatigue, low mood, low libido) for weeks to months; hCG, FSH or clomiphene-assisted protocols shorten this under specialist care. | If trying to conceive, plan on **6-12 months** with a semen analysis every \~3 months rather than assuming a quick rebound. | | **Cardiovascular and blood-pressure picture** | Not a fertility line item, but the reason monitoring exists: TRAVERSE reported **7.0% vs 7.3%** major adverse cardiac events (HR 0.96; 95% CI 0.78-1.17) in hypogonadal men aged 45-80 with existing or high cardiovascular risk, with **more atrial fibrillation (3.5% vs 2.4%), acute kidney injury (2.3% vs 1.5%) and pulmonary embolism (0.9% vs 0.5%)** on testosterone ([*NEJM* 2023](https://www.nejm.org/doi/full/10.1056/NEJMoa2215025?ref=dotsexual.com)). | Ambulatory blood-pressure study findings produced the class-wide **2025 FDA blood-pressure warning** while the cardiovascular boxed-warning language was removed. Both changes landed in the same action. | The trial titrated testosterone into a 350-750 ng/dL band and held Hct at or below 54%; "supraphysiologic self-escalation" is outside every safety dataset. | ## 4\. What the 2026 label changes do and do not say - **February 2025:** FDA's class-wide action added TRAVERSE results to labels, added or strengthened blood-pressure warnings, removed the cardiovascular-risk language from boxed warnings, and *retained* the age-related limitation of use ([FDA statement](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-issues-class-wide-labeling-changes-testosterone-products?ref=dotsexual.com)). Topical gels keep a boxed warning about **secondary transfer to children and women**, which the 2025 change did not touch. - **16 April 2026:** FDA encouraged sponsors of approved testosterone products to contact the agency about a potential *new indication* for low libido in idiopathic hypogonadism (docket applications due to be discussed from 30 April 2026). An invitation to submit evidence is not a clearance, and no product gained an "optimisation" or wellness indication. - **18 June 2026:** HHS said the FDA is asking sponsors to remove the age-related limitation of use, to narrow the prostate-cancer contraindication to **metastatic** disease, and to soften the benign-prostatic-hyperplasia warning while keeping monitoring for severe urinary symptoms. The agency's own release states long-term prostate safety "remains unestablished" because prostate cancer develops slowly and trials did not follow men long enough ([Reuters, 18 June 2026](https://www.reuters.com/business/healthcare-pharmaceuticals/us-health-department-proposes-testosterone-therapy-label-updates-2026-06-18/?ref=dotsexual.com); [AP summary](https://medicalxpress.com/news/2026-06-testosterone-therapy-limits-fda.html?ref=dotsexual.com)). - **16 July 2026 (three weeks after the label request):** the Endocrine Society published a statement going the other way on *diagnostic rigour*: symptoms plus consistently low, accurately measured total *and* free testosterone on repeated standardised morning assays; no population screening; treat reversible causes like obesity first; and it called for a men's-health trial on the Women's Health Initiative model to settle long-term safety ([Endocrine Society](https://www.endocrine.org/news-and-advocacy/news-room/2026/statement-on-testosterone-replacement-therapy?ref=dotsexual.com)). Read together with the June request, the direction of travel is: **more men may be eligible, and the testing bar is not being lowered.** ## 5\. The 8-question checklist to bring to a testosterone appointment 1. **"Have I had two early-morning draws, seven to ten a.m., on separate days?"** If not, ask for them before any prescription, not after the first month. 2. **"Which cut-off are you using: AUA 300 ng/dL or Endocrine Society 264 ng/dL, and was my free testosterone measured or calculated?"** In obesity, low SHBG makes total testosterone misleading, which is why the 2026 statement insists on both. 3. **"What was my haematocrit, and at what number do we act?"** Baseline above 50% should be explained before starting; 54% or higher on treatment is a treat-now number. 4. **"What is my blood pressure plan?"** Class-wide blood-pressure warnings now sit in every label; ask for a home cuff protocol. 5. **"Do I need a PSA test?"** AUA advises PSA before starting in men over 40; with the 2026 narrowing of the prostate warning, pre-treatment assessment and follow-up are the explicit trade. 6. **"What happens to my sperm count, and do we want children in the next two years?"** Get a baseline semen analysis and discuss sperm banking, hCG co-therapy or clomiphene instead of testosterone if conception is on the table ([Semen Sample Abstinence Rules](https://dotsexual.com/semen-sample-abstinence-rules/) explains how those samples are timed). 7. **"Am I on anything that changes the answer?"** Finasteride and dutasteride, opioids, corticosteroids, untreated sleep apnoea and heavy alcohol each depress testosterone or sperm independently. See [Finasteride Sexual Side Effects and Regulator Warnings](https://dotsexual.com/finasteride-sexual-side-effects-regulator-warnings-evidence/), and the guideline answer is to remove the reversible cause first. 8. **"What is the exit plan?"** A written "if we stop" plan (expected 6 to 12 months of recovery, what to monitor, and what contraception the couple needs meanwhile) is the mark of a clinic that reads guidelines rather than brochures. ## 6\. Two claims worth retiring this Movember **"Testosterone will fix my erections and my energy."** Randomised evidence is narrow. TRAVERSE's own design tells you the honest scope: men aged 45 to 80 with laboured hypogonadism and cardiovascular risk, titrated into 350-750 ng/dL, followed for an average of \~33 months, with more than 60% stopping study gel early. And [our audit of ashwagandha and shilajit trials versus adverts](https://dotsexual.com/ashwagandha-shilajit-testosterone-timing-evidence/) covers the same evidence gap from the supplement side, while the SMSNA's October 2026 ingredient analysis found commercial "testosterone boosters" rarely raise serum testosterone in otherwise healthy men, read alongside [Does Masturbation Lower Testosterone, Sperm Count or Erections?](https://dotsexual.com/masturbation-testosterone-sperm-erections-evidence/) before accepting any single-hormone explanation. For the vascular side of the erection question, see [Losing Your Erection With a Condom](https://dotsexual.com/losing-erection-with-condom/) and [Vaping, Nicotine and Erections](https://dotsexual.com/vaping-nicotine-erections-vascular-evidence/), and for the "is my anatomy the problem" question, [Average Penis Size: How Studies Measure](https://dotsexual.com/average-penis-size-how-studies-measure/). **"If I want to avoid pregnancy, low sperm count does it for me."** It does not. Suppression is deep in most men and incomplete in a real minority, and 5 to 10% retain enough spermatogenesis to cause a pregnancy. If pregnancy is not wanted, the [emergency-contraception clocks](https://dotsexual.com/emergency-contraception-pills-copper-iud-rules-by-country/) still apply after a condom failure, and our [Broken or Slipped Condom & Unprotected Exposure Action Responder on /tools/](https://dotsexual.com/tools/#ds-emergency-tool) gives you the 72-hour and 120-hour clocks that follow one. If a clinic will not answer those questions in writing, the [Talk to a Real Clinician](https://dotsexual.com/talk-to-a-clinician/) directory lists accredited urology, andrology and sexual-medicine routes in the US, UK, Canada and Australia, and our method is documented at [How We Research](https://dotsexual.com/how-we-research/). ## Frequently asked questions **What time of day should I have my testosterone drawn?** Between roughly 7 and 10 a.m., fasting, on two separate days. Testosterone peaks in the early morning and can fall substantially by late afternoon, so an afternoon draw can look "low" in a healthy man and normalise the next morning. **Is one low reading enough to start treatment?** No. Both the AUA and the Endocrine Society require repeat measurement, because intra-individual variability between draws is large enough that a single number is treated as a screening result, not a diagnosis. If the first is low and the second normal, guidelines allow a third draw and clinical judgement. **Do I still need contraception on testosterone?** Yes, if pregnancy is not wanted. Testosterone is not a licensed male contraceptive and does not reliably stop sperm production in every man; the flip side, that suppression severe enough to cause infertility, is exactly why fertility counselling belongs before the first dose. **Does the 2026 FDA change mean anyone can get a prescription?** No. It removes a cautionary "not established for age-related decline" sentence from labelling and opens a discussion about a low-libido indication; it does not authorise treating symptoms with normal labs, and it does not replace the two-morning-test requirement. **Should Movember be when I get checked?** It is as good a prompt as any, and the movement's own focus is prostate cancer, testicular cancer and men's mental health, not hormones. If you use the month to book bloods, ask for the full panel above rather than a single testosterone number, and read [our Movember 2026 guide to erectile dysfunction, penile fillers and the SMSNA warnings](https://dotsexual.com/movember-2026-erectile-dysfunction-under-40-penile-fillers-smsna-evidence/) for the procedures side of the same conversation. ## Sources and evidence notes 1. **Epic Research.** Most Men Starting Testosterone Had Prior Testing, but Only 1 in 5 Met the Two-Test Standard. 27 October 2026; 300,277 men, Cosmos dataset (310M+ records). [epicresearch.org](https://www.epicresearch.org/articles/most-men-starting-testosterone-had-prior-testing-but-only-1-in-5-met-the-two-test-standard/?ref=dotsexual.com). 2. **Mulhall JP, Trost LW, Brannigan RE, et al.** Evaluation and Management of Testosterone Deficiency: AUA Guideline. *J Urol* 2018;200(2):423-432 (validity affirmed 2024). [AUA Guideline portal](https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline?ref=dotsexual.com). 3. **The Endocrine Society.** Statement on Testosterone Replacement Therapy. 16 July 2026\. [Endocrine Society news release](https://www.endocrine.org/news-and-advocacy/news-room/2026/statement-on-testosterone-replacement-therapy?ref=dotsexual.com); analysis: [TouchEndocrinology](https://touchendocrinology.com/insight/new-endocrine-society-statement-reinforces-diagnostic-standards-for-testosterone-therapy/?ref=dotsexual.com). 4. **US FDA.** FDA issues class-wide labeling changes for testosterone products. 28 February 2025\. [fda.gov](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-issues-class-wide-labeling-changes-testosterone-products?ref=dotsexual.com); [FDA Takes Step Forward on Testosterone Therapy for Men, 16 April 2026](https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men?ref=dotsexual.com). 5. **HHS/FDA requested labelling revisions.** Reuters, 18 June 2026\. [reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-health-department-proposes-testosterone-therapy-label-updates-2026-06-18/?ref=dotsexual.com); [AP summary](https://medicalxpress.com/news/2026-06-testosterone-therapy-limits-fda.html?ref=dotsexual.com); [Healio analysis](https://www.healio.com/news/endocrinology/20260619/hhs-proposes-changes-to-loosen-warnings-on-testosterone-therapy?ref=dotsexual.com). 6. **Lincoff AM, et al.** Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). *N Engl J Med* 2023;389:107-117 (NCT03518034). [NEJM](https://www.nejm.org/doi/full/10.1056/NEJMoa2215025?ref=dotsexual.com); clinician commentary: [Cleveland Clinic](https://consultqd.clevelandclinic.org/traverse-study-supports-cardiovascular-safety-of-testosterone-therapy-when-used-as-indicated?ref=dotsexual.com). 7. **Crosnoe KE.** Exogenous testosterone: a preventable cause of male infertility. *Transl Androl Urol* 2013 (synthesis of WHO male-pill programme data: 65% azoospermia at 6 months, mean 120 days to suppression, 67/90/96/100% recovery at 6/12/16/24 months). [tau.amegroups.org](https://tau.amegroups.org/article/view/2249/html?ref=dotsexual.com). 8. **Papaleontiou M, et al.** Guideline-concordant diagnostic testing before testosterone initiation. ENDO 2026, Chicago, 13-16 June 2026\. [Renal & Urology News](https://www.renalandurologynews.com/news/endo-few-men-receiving-testosterone-undergo-guideline-concordant-diagnostic-testing?ref=dotsexual.com). 9. **Prescribing-trend datasets.** [Truveta (September 2026): +121.8% in adults 18-34, 2018-2026](https://www.truveta.com/blog/research/testosterone-rise-adults/?ref=dotsexual.com); [Miami Herald/PLoS One (June 2026): 7.3M to 11M+ US prescriptions](https://www.miamiherald.com/living/article316019857.html?ref=dotsexual.com); [NHS prescription data +52%, UK (October 2026)](https://britbrief.co.uk/health/public/testosterone-supplement-surge-sparks-health-warning.html?ref=dotsexual.com); [Connecticut Monitoring Program +63% (July 2026)](https://ctmirror.org/2026/07/10/more-ct-residents-are-taking-testosterone/?ref=dotsexual.com). 10. **Movember.** Campaign dates and focus (prostate cancer, testicular cancer, men's mental health; November 2026). [us.movember.com](https://us.movember.com/about/cause?ref=dotsexual.com). *Evidence checked: 31 October 2026\. Written by the Dot Sexual Research Desk (*[*Dot*](https://dotsexual.com/about/)*). General educational synthesis of guideline and trial data; it is not a prescription, and testosterone therapy decisions belong with a clinician who has seen your labs. Corrections policy:* [*Corrections*](https://dotsexual.com/corrections/)*.*